Innovative Technology EmendoBio specializes in next-generation gene editing tools leveraging protein engineering, positioning it as a pioneering company with disruptive solutions ideal for biotech firms seeking advanced genetic technologies.
Strategic Collaborations The recent partnership with Anocca AB for licensing the OMNI-A4 nuclease demonstrates EmendoBio's active role in expanding its technology reach and potential to integrate with other biotech innovations, creating opportunities for joint development projects.
Strong Funding Support With a substantial funding of $250 million and a revenue range of $10 to $25 million, EmendoBio has solid financial backing to scale its research and development efforts, Making it an attractive partner for future collaborations and investment opportunities.
Growth Potential Being a relatively small company with 11-50 employees and actively working within the competitive biotech space, EmendoBio offers growth opportunities for suppliers of biotech equipment, assay technologies, and research services to support its development pipeline.
Market Positioning Positioned alongside notable competitors in gene editing, EmendoBio's focus on resolving technological bottlenecks in gene therapy highlights its potential for strategic alliances with pharma and biotech firms looking to innovate in genetic therapeutics.
$250M$500M
$1M$10M
$25M$50M
$50M$100M
$250M$500M
$100M$250M
$50M$100M
$250M$500M
$10M$25MEmendoBio uses 8 technology products and services including OneTrust, MySQL, Microsoft 365, and more. Explore EmendoBio's tech stack below.
| EmendoBio Email Formats | Percentage |
| First@emendobio.com | 65% |
| FirstL@emendobio.com | 31% |
| Last@emendobio.com | 2% |
| First.Last@emendobio.com | 2% |
Biotechnology ResearchNew York, United States11-50 Employees
EmendoBio develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.
Company Overview
Funding & FinancialsEmendoBio has raised a total of $250M of funding over 3 rounds. Their latest funding round was raised on Dec 15, 2020 in the amount of $250M.
EmendoBio's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsEmendoBio has raised a total of $250M of funding over 3 rounds. Their latest funding round was raised on Dec 15, 2020 in the amount of $250M.
EmendoBio's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com